What are you looking for?

Dr. Wyatt McDonnell is Co-Founder and CEO of Infinimmune, a preclinical antibody biotechnology company treating human disease with truly human antibody therapeutics. Infinimmune’s discovery platform has produced two development candidates — IFX-101 (anti-IL-22) and IFX-201 (anti-IL-13) — and underpins a multi-target antibody discovery collaboration with Merck valued at up to $838 million in milestones. Previously, Wyatt worked on world-class single cell technologies at 10x Genomics where he was Technical Lead and Developer of Barcode-Enabled Antigen Mapping (BEAM). Wyatt developed 10x Genomics’ first therapeutic antibodies and core immunology intellectual property behind three commercial products to interrogate the immune repertoire. He has co-authored 43 peer-reviewed papers in journals including Nature, Cell, and Nature Medicine, and 44 published patents in antibody discovery and engineering, immunobiology, genomics, and in silico antibody models. He has been invited to speak at conferences including PEGS, the Keystone Symposia, Antibody Engineering and Therapeutics, the Antibody Series, the World Vaccine Congress, LEAP, and PMWC. 

Every human carries an archive of antibodies written, edited, and affinity-matured over a lifetime—selected against real antigens, passed through cellular quality control, and proven for expression, stability, and function inside a living person. This memory B cell repertoire is the source of most antibody therapeutics, yet it remains largely unread. 

Infinimmune reads this archive directly. Complete Human® recovers full-length, natively paired heavy- and light-chain sequences from 5′ to 3′ UTR at single-cell resolution. Anthrobody®, a library-on-B-cell screen, assigns antigen specificity across hundreds of pooled targets and millions of memory B cells. 

This end-to-end view reveals the true structural and functional diversity of antibodies taken straight out of humans, spanning both the Fv and the often-overlooked Fc—diversity that informs engineering of half-life, isoelectric point, and viscosity, properties central to developability and formulation. 

Infinimmune’s platform data trains GLIMPSE™, a human-first antibody language model that matches or exceeds published source-available models with over 100-fold fewer parameters, enabling zero-shot humanization, one-shot diversification, and engineering of affinity, potency, and manufacturing liabilities. 

This discovery-to-engineering loop is the source of Infinimmune’s pipeline, including IFX-101 (anti-IL-22), recovered from a single human B cell, and IFX-201 (anti-IL-13).